Recent Price Movements and Market Context
On 24 Feb 2026, Rossari Biotech’s share price fell by 1.87%, underperforming the Sensex’s decline of 0.95% on the same day. This drop extended a two-day losing streak, during which the stock has declined by 1.77%. Over the past week, the stock has fallen 3.57%, compared to a 1.14% decrease in the Sensex. The one-month performance shows a sharper decline of 6.27%, contrasting with a 1.18% gain in the benchmark index.
Longer-term trends reveal a more pronounced underperformance. Over three months, Rossari Biotech’s stock has dropped 17.17%, while the Sensex declined by only 2.82%. The one-year return is negative at -19.66%, starkly contrasting with the Sensex’s 10.81% gain. Year-to-date, the stock is down 14.03%, compared to a 3.19% fall in the Sensex. Over three and five years, the stock has declined by 24.75% and 52.19% respectively, while the Sensex has surged 38.74% and 62.47% in the same periods. Notably, the stock’s 10-year return stands at 0.00%, against the Sensex’s 257.33% rise.
Technical Indicators and Moving Averages
Rossari Biotech is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward momentum and a lack of short-term recovery signals. The stock’s performance today also lagged behind its sector, underperforming by 0.41%.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Financial Metrics and Ratings Overview
Rossari Biotech’s Mojo Score currently stands at 36.0, with a Mojo Grade of Sell, downgraded from Hold on 8 Dec 2025. The company’s market capitalisation grade is rated 3, reflecting its mid-tier valuation status within the specialty chemicals sector.
Key financial ratios highlight areas of concern. The operating profit to interest coverage ratio for the latest quarter is at a low 8.98 times, indicating tighter margins for servicing debt. The return on capital employed (ROCE) for the half-year period is 12.97%, the lowest recorded, signalling diminished efficiency in capital utilisation. The debt-to-equity ratio has increased to 0.28 times, the highest level for the company, though it remains relatively modest compared to industry standards.
Despite these figures, the company maintains a low average debt-to-equity ratio of 0.07 times, suggesting a conservative approach to leverage overall. The ROCE of 13.2% is accompanied by an enterprise value to capital employed ratio of 2, indicating an attractive valuation relative to capital base. However, the price-to-earnings-to-growth (PEG) ratio is elevated at 17.9, reflecting a disparity between earnings growth and current valuation.
Performance Relative to Benchmarks and Peers
Rossari Biotech has consistently underperformed the BSE500 index over the past three annual periods. Its negative return of 19.66% in the last year contrasts sharply with the broader market’s positive trajectory. This persistent lag has contributed to the stock’s declining market perception and valuation pressures.
Profit growth over the past year has been modest, with a 1.2% increase despite the stock’s negative price performance. This divergence between earnings and share price suggests market concerns beyond immediate profitability, possibly related to broader sector dynamics or company-specific factors.
Institutional Holdings and Market Position
Institutional investors hold a significant 20.59% stake in Rossari Biotech, indicating a level of confidence from entities with extensive analytical resources. This ownership concentration may influence trading patterns and liquidity but has not prevented the recent downward trend in share price.
Holding Rossari Biotech Ltd from Specialty Chemicals? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Current Situation
The all-time low price of Rs.501.65 reached by Rossari Biotech Ltd underscores a period of sustained underperformance relative to both sector peers and broader market indices. The stock’s decline is accompanied by subdued financial ratios, including reduced operating profit coverage and ROCE, alongside a modest increase in leverage. While valuation metrics suggest some attractiveness, the elevated PEG ratio and consistent negative returns over multiple timeframes highlight ongoing challenges in market perception.
Trading below all major moving averages, the stock’s technical outlook remains weak. Institutional holdings remain significant, yet have not stemmed the downward momentum. The company’s financial data and market performance collectively illustrate a complex scenario that has culminated in this historic low share price.
Conclusion
Rossari Biotech Ltd’s recent all-time low price reflects a combination of financial pressures and market dynamics that have influenced its valuation and investor sentiment. The stock’s performance over various time horizons has lagged behind key benchmarks, and key financial ratios indicate areas of concern. This situation provides a comprehensive view of the company’s current standing within the specialty chemicals sector as of February 2026.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
